Research presented at the American Academy of Neurology's annual meeting indicates some air pollutants may be associated with increased rates of migraine prevalence and severity.
Ambient air pollutants such as nitrogen dioxide (NO2) and ozone may be associated with increased migraine prevalence and severity, according to research presented at the American Academy of Neurology’s 73rd Annual Meeting, being held virtually April 17-22, 2021.
NO2 is an air pollutant generated from automobiles and fuel combustion. It is also involved in the secondary formation of particulate matter (PM), and even short-term exposure to the pollutant can increase the risk of death from respiratory disease.
Previous research has explored the relationship between the effects of weather on migraine and found that higher relative humidity was associated with greater odds of migraine onset in warm season months. However, one study conducted in 2019 found a weak positive association between air pollutants and higher odds of migraines in the cold season.
To better understand the implications of environmental exposures for migraine in patients in one geographical region, investigators used a migraine probability algorithm (MPA) to assess migraine cases and controls among Sutter Health patients in Northern California.
“Prior studies report associations between fine particles (PM2.5), NO2, and ozone and migraine-related emergency department (ED) visits,” authors wrote. “To our knowledge, none have evaluated the importance of methane super-emitters or oil and gas wells, nor have any considered alternative proxies for migraine exacerbation beyond ED visits,” they added.
Between 2014 and 2018, a total of 89,575 migraine cases were identified at the health system, in addition to 270,564 frequency-matched controls. “Exposures included 2015 annual average block group-level PM2.5 and NO2 concentrations, inverse-distance weighted (IDW) methane emissions from super-emitters within 10km of participant residences between 2016–2018, and 2015 IDW active oil and gas wells within 10km of participant residences,” researchers explained.
To evaluate the association between environmental exposures and migraine case status and severity, researchers used logistic and negative binomial mixed models controlled for age, sex, race/ethnicity, Medicaid eligibility, primary care visits, population density and community poverty. Migraine severity was defined as an MRP score greater than 100, triptan prescriptions, neurologist visits, urgent care migraine visits and ED migraine visits.
Analyses revealed:
Despite these links, overall, researchers “observed limited associations between continuous measures of methane emissions and proximity to oil and gas wells and migraine severity.”
Reference
Elser H, Morello-Frosch R, Jacobson A, et al. Air pollution, methane super-emitters, and oil and gas wells in Northern California: the relationship with migraine headache prevalence and exacerbation. Presented at: American Academy of Neurology 73rd Annual Meeting; April 17-22, 2021; Virtual. Accessed April 20, 2021. https://index.mirasmart.com/AAN2021/PDFfiles/AAN2021-001194.html
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials
October 11th 2024An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.
Read More